Evidence map›Paper›PMID 30201971›Full record

ArticleNature communications2018

ER-associated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes.

Juncheng Wei, Yanzhi Yuan, Lu Chen, Yuanming Xu, Yuehui Zhang, Yajun Wang, Yanjie Yang, Clara Bien Peek, Lauren Diebold, Yi Yang and 10 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Juncheng WeiDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Yanzhi YuanState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China.
Lu ChenDepartment of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, 100730, Beijing, China.
Yuanming XuDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Yuehui ZhangState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China.
Yajun WangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Yanjie YangDepartment of Medical Psychology, Public Health Institute of Harbin Medical University, 150081, Harbin, China.
Clara Bien PeekDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Lauren DieboldDepartment of Medicine, Northwestern University Feinberg School of Mdicine, Chicago, IL, 60611, USA.
Yi YangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Beixue GaoDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Chaozhi JinState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China.
Johanna Melo-CardenasDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Navdeep S ChandelDepartment of Medicine, Northwestern University Feinberg School of Mdicine, Chicago, IL, 60611, USA.
Donna D ZhangDepartment of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, 85721, USA.
Hui PanDepartment of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, 100730, Beijing, China.
Kezhong ZhangCenter for Molecular Medicine and Genetics, Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
Jian WangState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China. wangjian@bmi.ac.cn.
Fuchu HeState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China. hefc@bmi.ac.cn.
Deyu FangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. fangd@northwestern.edu.
Northwestern University · USBeijing Proteome Research Center · CNPeking Union Medical College Hospital · CNUniversity of Arizona · USWayne State University · US

Funding

SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
Tissue resident macrophages regulate proteostasis in the aging lungP01AG049665 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GR Scott Budinger · 2015 to 2026
$26.9M
Regulation of Hepatic Steatosis by an ER Stress-Inducible Transcription Factor CRR01DK090313 · NIDDK · WAYNE STATE UNIVERSITY · PI Kezhong Zhang · 2011 to 2026
$5.0M
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunityR01AI079056 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI FANG, DEYU · 2008 to 2017
$3.3M
The roles of Synoviolin in immune tolerance and autoimmunityR01AI108634 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU · 2014 to 2017
$1.5M
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunityR56AI079056 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU · 2012 to 2012
$386k
NIAID NIH HHS R01 AI079056NIAID NIH HHS R01 AI108634NIAID NIH HHS R56 AI079056NIA NIH HHS P01 AG049665NIDDK NIH HHS R01 DK090313NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

The HMG-CoA reductase degradation protein 1 (HRD1) has been identified as a key enzyme for endoplasmic reticulum-associated degradation of misfolded proteins, but its organ-specific physiological functions remain largely undefined. Here we show that mice with HRD1 deletion specifically in the liver display increased energy expenditure and are resistant to HFD-induced obesity and liver steatosis and insulin resistance. Proteomic analysis identifies a HRD1 interactome, a large portion of which includes metabolic regulators. Loss of HRD1 results in elevated ENTPD5, CPT2, RMND1, and HSD17B4 protein levels and a consequent hyperactivation of both AMPK and AKT pathways. Genome-wide mRNA sequencing revealed that HRD1-deficiency reprograms liver metabolic gene expression profiles, including suppressing genes involved in glycogenesis and lipogenesis and upregulating genes involved in glycolysis and fatty acid oxidation. We propose HRD1 as a liver metabolic regulator and a potential drug target for obesity, fatty liver disease, and insulin resistance associated with the metabolic syndrome.

Indexed as

Endoplasmic Reticulum-Associated DegradationAdenylate KinaseAnimalsBody WeightDiet, High-FatEndoplasmic ReticulumEnzyme ActivationFatty AcidsGene DeletionGene Expression RegulationGenome-Wide Association StudyGlycolysisHEK293 CellsHep G2 CellsHumansLipogenesisAdenylate KinaseFatty AcidsProteomeSyvn1 protein, mouseTriglyceridesUbiquitin-Protein Ligases

Identifiers

PMID30201971
PMCPMC6131148
OpenAlexW2890182286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.